Australia is closely awaiting the arrival of retatrutide, a innovative dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://bike-giant-stance412321.reflectblog.com/313429/novo-nordisk-s-retatrutide-australia-a-potential-solution-for-weight-management